Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Total Debt (2016 - 2025)

Historic Total Debt for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $2.0 million.

  • BioRestorative Therapies' Total Debt fell 4303.83% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 4303.83%. This contributed to the annual value of $2.5 million for FY2024, which is 371.22% down from last year.
  • Per BioRestorative Therapies' latest filing, its Total Debt stood at $2.0 million for Q3 2025, which was down 4303.83% from $2.6 million recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Total Debt high stood at $14.2 million for Q1 2022, and its period low was $308970.0 during Q4 2021.
  • In the last 5 years, BioRestorative Therapies' Total Debt had a median value of $4.5 million in 2021 and averaged $4.8 million.
  • In the last 5 years, BioRestorative Therapies' Total Debt plummeted by 9276.46% in 2021 and then skyrocketed by 169361.52% in 2022.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Total Debt stood at $308970.0 in 2021, then skyrocketed by 1693.62% to $5.5 million in 2022, then tumbled by 52.76% to $2.6 million in 2023, then fell by 3.71% to $2.5 million in 2024, then dropped by 21.92% to $2.0 million in 2025.
  • Its Total Debt was $2.0 million in Q3 2025, compared to $2.6 million in Q2 2025 and $3.2 million in Q1 2025.